Actelion hit with $547M judgment as insurgents rally

Just as Actelion's executive team was gearing up for a showdown on Thursday with a rebellious crew of insurgent shareholders, the company was hit with a big court judgment. A jury ruled that Asahi Kasei Pharma should get $547 million to settle its claims against Actelion in a licensing dispute that followed Actelion's $420 million buyout of CoTherix in 2007. Actelion says it may appeal. "The news is a clear negative for Actelion both sentiment-wise and fundamentally. Without the activist process we would struggle to keep the Buy rating," said Kepler Capital Markets analyst Tero Weckroth. Story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.